CAAS Capital Management’s European Biotech Acquisition Corp. Class A Ordinary Shares EBAC Stock Holding History

CAAS Capital Management’s Portfolio EBAC Stock Details EBAC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-96,710	Closed	-$977K	–	1023
2022 Q4	$977K	Hold	96,710	–	–	0.06%	282
2022 Q3	$958K	Hold	96,710	–	–	0.05%	373
2022 Q2	$947K	Buy	+96,710	New	+$947K	0.05%	393
2022 Q1	–	Sell	-96,710	Closed	-$937K	–	1042
2021 Q4	$937K	Hold	96,710	–	–	0.02%	452
2021 Q3	$935K	Buy	+96,710	New	+$935K	0.02%	512

CAAS Capital Management's EBAC Position: Q1 2023 in Review

CAAS Capital Management sold out of European Biotech Acquisition Corp. Class A Ordinary Shares (EBAC) in Q1 2023, closing a stake of 96,710 shares — an estimated $977K sold.

CAAS Capital Management first reported a position in EBAC in Q3 2021 and held it in 5 quarters. The position peaked at $977K in Q4 2022. 0 funds tracked by Wall St. Rank hold EBAC as of Q1 2023.

CAAS Capital Management reported no remaining European Biotech Acquisition Corp. Class A Ordinary Shares position as of Q1 2023 after selling out during the quarter.
CAAS Capital Management sold 96,710 European Biotech Acquisition Corp. Class A Ordinary Shares shares in Q1 2023, an estimated $977K.
CAAS Capital Management first reported a position in European Biotech Acquisition Corp. Class A Ordinary Shares in Q3 2021 and held it in 5 quarters.
CAAS Capital Management's European Biotech Acquisition Corp. Class A Ordinary Shares position peaked at $977K in Q4 2022.
0 funds tracked by Wall St. Rank held European Biotech Acquisition Corp. Class A Ordinary Shares as of Q1 2023.

Based on CAAS Capital Management's 13F filing for Q1 2023, filed 15 May 2023.